Global Aminoglycosides Market Size (2024 - 2029)

Aminoglycosides Market Analysis

The aminoglycosides market is expected to record a CAGR of 4.11% over the forecast period (2022-2027).

The COVID-19 outbreak significantly impacted the healthcare sector. As per the article published in 2021 under the title 'Aminoglycosides and their potential as SARS-CoV-2 antivirals', as the defense mechanism implemented by aminoglycosides, it was anticipated to be worth researching as SARS-CoV-2 antivirals. Moreover, murine hepatitis virus (MHV) inhibition by the aminoglycosides hygromycin B (hygB) and neomycin has been demonstrated in vitro. Furthermore, as per the article published in 2021 under the title 'Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents', Aminoglycosides were likely to be used as a base to create powerful COVID-19 medicinal compounds. Hence, as per the factors mentioned above, COVID-19 had a significant impact on the loratadine market.

The major factors driving the market growth include the growing instances of animal disease outbreaks, leading to the high utilization of antibiotics, a rise in the aging population, and the increasing prevalence of bacterial infectious diseases. For instance, as per the article published in 2022 under the title 'Correlation between antibiotic consumption and the occurrence of multidrug-resistant organisms in a Malaysian tertiary hospital: a 3-year observational study', the study showed that broad-spectrum antibiotics and antibiotics against multidrug-resistant organisms (MRO) consumption increased significantly throughout in the studied region. In humans and animals, the usage of aminoglycosides in the treatment of different bacterial infections is increasing due to the presence of characteristics such as bactericidal activity against staphylococci and certain mycobacteria, which is expected to influence market growth.

Moreover, this class of antibiotics is found to be effective even when bacterial inoculum is large, and it is frequently used as a second line of defense against basic infection resistant to basic antibacterial. The increasing burden of tuberculosis is also expected to drive the demand for aminoglycosides, especially in low-income countries where the incidence is alarmingly high and there is a need for aminoglycosides. For instance, as per the World Health Organization (WHO) 2021 update, a total of 1.5 million people died from tuberculosis in 2020 (including 214,000 people with HIV). Globally, COVID-19 (after HIV/AIDS) is the second most lethal infectious disease, while tuberculosis is the 13th most common cause of death.

As per the facts mentioned above aminoglycosides, market is expected to grow over the forecast period. However, a reduction in the prescription rate of aminoglycoside antibiotics due to side effects associated with the usage of these drugs which include severe ototoxicity, nephrotoxicity, and neuromuscular blockade is expected to restrain the market growth.

Aminoglycosides Industry Segmentation

As per the scope of this report, aminoglycosides are highly potent antibiotics with several properties for the treatment of life-threatening infections. Aminoglycosides have concentration-dependent bactericidal activity by binding to the 30S ribosome that inhibits bacterial protein synthesis. The aminoglycosides market is segmented by product (Neomycin, Tobramycin, Gentamycin, Streptomycin, Kanamycin, Paromomycin, Amikacin, Verdamicin, Astromicin, and Hygromycin B), route of administration (parenteral, intra-mammary, topical, and oral), application (veterinary, skin infection, respiratory diseases, UTI and pelvic diseases, and other diseases), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.